Latin America BFS Technology Market Analysis & Forecast: 2026-2033
The Latin America BFS Technology Market size is anticipated to grow at a CAGR of 6% with USD 450 Mn in 2026 and is expected to reach USD 673.6 Mn in 2033. The primary drivers are defined by the expanding pharmaceutical manufacturing base, rising demand for sterile unit-dose packaging, increasing chronic disease burden, and wider adoption of aseptic filling technologies across Latin America. Some of the other factors include growth in ophthalmic and respiratory medicines, vaccine and biologics production, hospital procurement, contract manufacturing, regulatory emphasis on contamination control, lightweight recyclable packaging, longer product shelf life, and demand for bottles, ampoules, vials, prefilled syringes, and large-volume nebulizers. According to PAHO, 62 Mn people live with diabetes in the Americas, supporting sustained demand for BFS-packaged pharmaceutical and healthcare products across the region.
On the basis of product type, the bottles segment is projected to account for the largest Latin America BFS Technology Market share of 41.2% in 2026. The segment’s growth is owing to the suitability for medium- and large-volume liquids, compatibility with hospital workflows, low breakage risk, and ability to replace glass bottles or flexible bags in selected applications. BFS bottles are used for irrigation solutions, intravenous fluids, antiseptics, topical preparations, oral liquids, dialysis-related solutions, and pharmaceutical bulk-dose products.
The continuous BFS process eliminates several separate operations associated with conventional bottle packaging, including container washing, sterilization, transport to a filling line, closure feeding, and capping. Rommelag reports that its large-volume BFS equipment supports bottles from 100 mL to 1,000 mL and can achieve output of up to 9,200 bottles per hour. Its latest 500 Series can operate with approximately seven square metres of Class C cleanroom space, helping manufacturers reduce facility complexity and controlled-area operating costs.
To learn more about this report, Request Free Sample
On the basis of material type, the Polyethylene (PE) segment is projected to account for the largest Latin America BFS Technology Market share of 61.5% in 2026. The segment’s growth is owing to the processing flexibility, impact resistance, low density, relatively economical production, and widespread availability in pharmaceutical-compatible grades. Low-density polyethylene is particularly suitable for squeezable ophthalmic and respiratory ampoules, while high-density polyethylene can provide additional rigidity for bottles and selected multidose products.
Polyethylene containers can be formed directly from resin within a BFS machine, reducing the need to purchase, sterilize, store, and feed preformed containers. This integration helps pharmaceutical manufacturers lower container-handling requirements and reduce potential contamination points. For BFS products, FDA guidance recommends that extractables be evaluated using the fully formed drug-product container rather than only the unprocessed resin.
Brevetti Angela reports that its SYFPAC machinery can process polyethylene, high-density polyethylene, and polypropylene on the same equipment, allowing manufacturers to select material characteristics according to formulation and container requirements.
Argentina is becoming an important center for vaccine localization, technology transfer, biologic manufacturing, and advanced fill-finish capabilities in Latin America. Domestic companies are working with international organizations and global pharmaceutical manufacturers to expand regional access to complex vaccines. This trend creates opportunities for BFS technology, particularly as manufacturers explore polymer-based unit-dose systems, compact prefilled injectors, low-temperature filling, as well as integrated aseptic packaging for biologically sensitive products.
In June 2025, PAHO, WHO, and the Medicines Patent Pool supported Sinergium Biotech’s development of an mRNA vaccine against influenza A(H5N1) in Argentina. Sinergium was undertaking preclinical work while constructing a new mRNA vaccine production plant expected to become operational during 2026. Argentina is also expected to share technical knowledge from the initiative with other low- and middle-income countries through the WHO mRNA Technology Transfer Programme. This development strengthens Argentina’s position in advanced pharmaceutical manufacturing and is expected to create future opportunities for automated aseptic filling, low-temperature BFS, prefilled delivery devices, and specialized contract manufacturing.
Closed-parison BFS technology represents an important advancement for aseptic pharmaceutical production. In a conventional BFS process, pharmaceutical-grade polymer is extruded into a parison, formed into a container, filled with the pharmaceutical formulation, and sealed within one continuous operation. Closed-parison systems further isolate critical filling operations from the surrounding environment, thereby improving both process control as well as reducing contamination risks.
In December 2024, Brevetti Angela introduced its SYFPAC DUO closed-parison BFS platform. The system is designed for filling volumes between 0.2 mL and 50 mL and can operate at rates ranging from 4,000 units per hour to 40,000 units per hour, equivalent to a potential annual output of approximately 264 million doses. The platform can process polyethylene, polypropylene, and high-density polyethylene without hardware changes and can complete mould changeovers in less than ten minutes.
|
Current Event |
Description and its Impact |
|
Mexico’s 2025 Abbreviated Regulatory Pathway for Medicines and Health Supplies |
|
|
Expansion of Regional Pharmaceutical Manufacturing and Pooled Procurement in 2025 |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The Brazil is expected to dominate the market with 41.8% share in 2026. The country’s growth is owing to the high domestic medicine consumption with public procurement, local vaccine institutions, biologic research, and established regulatory capabilities. Its large ophthalmic, respiratory, hospital-care, and generic-drug sectors create opportunities for both small-volume and large-volume BFS systems.
PAHO recognizes ANVISA as one of the regional reference regulatory authorities used to assess quality-assured health technologies for procurement. This strengthens Brazil’s ability to manufacture products intended for regional distribution.
The country’s RNA Competence Center and vaccine collaboration programs are expected to increase demand for advanced sterile manufacturing capabilities. While not all biologics are immediately compatible with BFS, lower-temperature systems, closed-parison processing, and integrated delivery devices could widen adoption.
Argentina is expected to be the fastest-growing country in Latin America. The growth is supported by the companies such as Sinergium Biotech, public-health partnerships, regulatory expertise under ANMAT, and increasing participation in regional vaccine supply programs.
In January 2025, PAHO announced that Argentina, Pfizer, and Sinergium were advancing local production of the PCV20 pneumococcal vaccine, with initial Argentine-produced doses expected during 2026. The vaccine is intended for children below two years of age and adults over 60, both important patient groups for public immunization.
Sinergium’s mRNA H5N1 vaccine work and new production facility are also strengthening demand for high-quality fill-finish infrastructure. These investments could create opportunities for BFS suppliers as Argentine manufacturers assess compact prefilled systems, polymer-based sterile containers, and scalable aseptic production.
Some of the major key players in Latin America BFS Technology Market are Unither Pharmaceuticals, Takeda Pharmaceuticals International AG, Brevetti Angela S.R.L., Unipharma, LLC, Rommelag Kunststoff-Maschinen Vertriebsgesellschaft mbH, Horizon Pharmaceuticals, Inc., Weiler Engineering Inc., and Nephron Pharmaceuticals Corporation.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 450 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6% | 2033 Value Projection: | USD 673.6 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Unither Pharmaceuticals, Takeda Pharmaceuticals International AG, Brevetti Angela S.R.L., Unipharma, LLC, Rommelag Kunststoff-Maschinen Vertriebsgesellschaft mbH, Horizon Pharmaceuticals, Inc., Weiler Engineering Inc., and Nephron Pharmaceuticals Corporation |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Pankaj Poddar is a seasoned market research consultant with over 12 years of extensive experience in the fast-moving consumer goods (FMCG) and plastics material industries. He holds a Master’s degree in Business Administration with specialization in Marketing from Nirma University, one of India’s reputed institutions, which has equipped him with a solid foundation in strategic marketing and consumer behavior.
As a Senior Consultant at CMI for the past three years, he has been instrumental in harnessing his comprehensive understanding of market dynamics to provide our clients with actionable insights and strategic guidance. Throughout his career, He has developed a robust expertise in several key areas, including market estimation, competitive analysis, and the identification of emerging industry trends. His approach is grounded in a commitment to understanding client needs thoroughly and fostering collaborative relationships. His dedication to excellence and innovation solidifies his role as a trusted advisor in the ever-evolving landscape of not only FMCG but also chemicals and materials markets.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
